(Q28575953)

31 January 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation (English)

2 references

31 January 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Gaoping Chen

1

2 references

31 January 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Kanishka Sircar

2

2 references

31 January 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Armen Aprikian

3

2 references

31 January 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Anil Potti

4

2 references

31 January 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

David Goltzman

5

2 references

31 January 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

2 references

31 January 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

107

2 references

31 January 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

2

2 references

31 January 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

289-298

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

RANK is essential for osteoclast and lymph node development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Metastasis to bone: causes, consequences and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Expression and somatic mutation on androgen receptor gene in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Osteoprotegerin and rank ligand expression in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Prostate cancer bone metastases promote both osteolytic and osteoblastic activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Osteoprotegerin in prostate cancer bone metastasis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21978

7 January 2021

Identifiers

DOI

10.1002/CNCR.21978

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752412%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017